Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05226598
Title Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + MK-7684A + Paclitaxel

Cisplatin + Pembrolizumab + Pemetrexed Disodium

Cisplatin + MK-7684A + Pemetrexed Disodium

Carboplatin + MK-7684A + Nab-paclitaxel

Carboplatin + MK-7684A + Pemetrexed Disodium

Carboplatin + Paclitaxel + Pembrolizumab

Carboplatin + Nab-paclitaxel + Pembrolizumab

Carboplatin + Pembrolizumab + Pemetrexed Disodium

Age Groups: senior | adult
Covered Countries USA | FRA | ESP | DEU | AUT


No variant requirements are available.